handling proteins changes identified, an enhanced I NaL seems to be a major contributor to the electrophysiological and Ca 
H ypertrophic cardiomyopathy (HCM) is the most prevalent monogenic cardiac disorder, with a reported prevalence of 1 in 500 worldwide. 1 Despite its epidemiological relevance, HCM is largely an orphan condition because it lacks a disease-specific pharmacological treatment. 2 HCM is the most common cause of arrhythmic sudden cardiac death in young athletes. 3 Enhanced ventricular arrhythmogenicity in HCM has been attributed to multiple abnormalities such as abnormal cardiomyocyte orientation and alignment (disarray), microvascular ischemia, and intramyocardial fibrosis. 4 Conversely, more subtle changes occurring at the molecular and cellular levels, causing electrophysiological disturbances and likely playing a crucial role in triggering arrhythmias, have received limited attention and remain unresolved. Furthermore, by impairing intracellular calcium (Ca 2+ i ) handling, electrophysiological abnormalities are potentially implicated in diastolic dysfunction, another pathophysiologic hallmark of the disease. 5 Thus, preclinical studies defining the cellular basis for the enhanced arrhythmogenesis and impaired diastolic function represent a plausible starting point in the search for disease-specific therapeutic targets in HCM.
Clinical Perspective on p 584
In this study, we aimed to characterize the electrophysiological profile, Ca 2+ i handling properties, and contractile function of isolated cardiomyocytes and trabeculae from patients Background-Hypertrophic cardiomyopathy (HCM), the most common mendelian heart disorder, remains an orphan of disease-specific pharmacological treatment because of the limited understanding of cellular mechanisms underlying arrhythmogenicity and diastolic dysfunction. . Such changes were related to enhanced Ca 2+ /calmodulin kinase II (CaMKII) activity and increased phosphorylation of its targets. Ranolazine at therapeutic concentrations partially reversed the HCM-related cellular abnormalities via I NaL inhibition, with negligible effects in controls. By shortening the action potential duration in HCM cardiomyocytes, ranolazine reduced the occurrence of early and delayed afterdepolarizations. Finally, as a result of the faster kinetics of Ca 2+ i transients and the lower diastolic Ca 2+ i , ranolazine accelerated the contraction-relaxation cycle of HCM trabeculae, ameliorating diastolic function. Conclusions-We highlighted a specific set of functional changes in human HCM myocardium that stem from a complex remodeling process involving alterations of CaMKII-dependent signaling, rather than being a direct consequence of the causal sarcomeric mutations. Among the several ion channel and Ca undergoing surgical myectomy and to test the potential reversal of disease-related abnormalities by inhibition of the late Na + current (I NaL ). In addition, we explored the role of Ca 2+ /calmodulin-dependent protein kinase II (CaMKII) as a potential mechanism underlying the electromechanical abnormalities in HCM. Preliminary data have been presented in abstract form. 6 
Methods and Results-We

Methods
An expanded Methods section is available in the online-only Data Supplement.
Patients Cohorts
The study conforms with the principles of World Medical Association's Declaration of Helsinki for medical research involving human subjects. The experimental protocols were approved by the ethics committee of Careggi University Hospital (2006/0024713; renewed May 2009). Each patient gave written informed consent. We enrolled 26 HCM patients from the Referral Center for Cardiomyopathies in Florence, Italy, consecutively referred to surgical myectomy for relief of drug-refractory symptoms related to left ventricular outflow tract obstruction. Of the 26 patients, 20 agreed to undergo mutational screening in sarcomeric genes.
The control cohort comprised 8 patients <65 years of age who were undergoing heart surgery for mitral steno-insufficiency, aortic stenosis, or regurgitation. Only patients with absent left ventricular hypertrophy (septal thickness <14 mm) and normal left ventricular systolic function (ejection fraction >55%) were included. Additionally, septal specimens from 13 nontransplanted donor hearts were included as controls for Western blot and reverse transcription-polymerase chain reaction experiments.
Tissue Processing
Septal specimens from HCM and control patients were washed and rapidly processed. Briefly, a small portion of the tissue was frozen in liquid nitrogen and used for protein and mRNA isolation. Endocardial trabeculae suitable for mechanical measurements were dissected, and the remaining tissue was minced and subjected to enzymatic dissociation to obtain viable single myocytes.
Protein Studies
Immunoprecipitation and Western blot analysis were performed by a standard method 7 on proteins isolated from control and HCM septal specimens using antibodies for the following native or phosphorylated proteins: CaMKIIδ, CaV1.2, SERCA2a, PLB, NCX1, NaV1.5.
Reverse Transcription-Polymerase Chain Reaction
mRNA isolated from septal specimens underwent reverse transcription, and the resulting cDNA was used for quantitative real-time polymerase chain reaction using predesigned assays (Life Technologies, Carlsbad, CA) for the following genes: KCND3 (Kv4. 3 
Single-Cell Studies
Perforated patch whole-cell voltage clamp and current clamp were used to measure Ca 2+ current and membrane potential, respectively. Ca ) was calculated from emitted fluorescence as previously described 8 using 389 nmol/L as the Fluoforte dissociation constant. Ruptured-patch voltage clamp was used to record transient outward (I to ) and inward (I k1 ) rectifier potassium currents and late Na + current (I NaL ) and to quantify sarcoplasmic reticulum (SR) calcium content from caffeine-activated Na + /Ca 2+ exchanger (NCX) current integration. Specific protocols and solutions were used to measure each current (see the expanded Methods section in the online-only Data Supplement).
Intact Trabeculae Studies
Ventricular trabeculae were mounted between a force transducer and a motor for muscle length control; isometric force was recorded under various experimental conditions and stimulation protocols. In brief, inotropic responses to increased pacing frequencies, stimulation pauses, and β-adrenoceptor agonists were evaluated, and kinetics of isometric twitches was measured under all conditions.
Ranolazine Studies
For experiments on isolated cardiomyocytes and trabeculae, ranolazine was used at the concentration of 10 µmol/L. Test recordings in the presence of the drug were performed after >3 minutes from the beginning of drug exposure. Afterward, the drug was washed out for >5 minutes, and measurements were repeated.
Statistics
Data from cells and muscles are expressed as mean±SEM. Statistical analysis, taking into account nongaussian distribution, inequality of variances, and within-subject correlation, was performed as detailed in the expanded Methods section in the online-only Data Supplement.
For categorical data, we used the Fisher exact test. For numerical variables, P values were calculated with linear mixed models. Values of P<0.05 were considered statistically significant.
Results
Myocardial tissue from 26 HCM patients undergoing septal myectomy was harvested and processed. Clinical and genetic features are summarized in Table I in the online-only Data Supplement. Notably, 13 patients (50%) had a history of nonsustained ventricular tachycardia on Holter monitoring, and all patients showed moderate to severe diastolic dysfunction. Clinical data for the control cohort are shown in Table II The action potential durations (APDs) recorded at various stimulation frequencies (0.2, 0.5, 1 Hz) were markedly prolonged in HCM compared with control cardiomyocytes ( Figure 1A ) and with greater APD variability among myocytes ( Figure 1B) . Consistent with APD prolongation, our patients often showed prolonged QTc on the ECG (Table I in the onlineonly Data Supplement) . 9 In HCM cardiomyocytes, maximum action potential upstroke velocity was slower ( Figure I in the online-only Data Supplement).
APD prolongation leads to increased frequency of early afterdepolarizations (EADs), 10 that is, spontaneous depolarizations during the plateau phase of the action potential, often associated with reopening of Na + or Ca 2+ channels. 11 EADs are considered primary electrophysiological triggers for ventricular tachyarrhythmias. 10 Indeed, EADs were 4 times more by guest on April 14, 2017 http://circ.ahajournals.org/ Downloaded from frequent in HCM cardiomyocytes than in controls ( Figure 1D ). Interestingly, cardiomyocytes from 13 HCM patients with a history of nonsustained ventricular tachycardia displayed increased APD and a higher occurrence of EADs compared with those from the remaining 13 patients without nonsustained ventricular tachycardia ( Figure 1C ). This observation highlights a possible correlation between APD prolongation and clinical history of ventricular arrhythmias in HCM patients. Furthermore, delayed afterdepolarizations (DADs), occurring during the diastolic period and related to spontaneous Ca 2+ release, were more frequent in HCM than in control cardiomyocytes ( Figure 1E ), suggesting additional arrhythmogenic mechanisms.
Interestingly, the degree of APD prolongation was similar in cardiomyocytes from HCM patients regardless of the presence or absence of sarcomeric mutations and regardless of the mutation site ( Figure 1F ). This observation suggests that prolongation of APD, rather than a direct consequence of the causing mutation, is the result of a complex process of hypertrophic remodeling involving multiple signaling pathways and modifying genes.
Altered Balance Between Inward and Outward Currents Underlies APD Prolongation in HCM
Na
+ current was evoked by depolarizing steps to −20 mV (from −120-mV holding potential) and the late component (I NaL ) calculated as an integral of the tetrodotoxin-sensitive inward current between 50 and 750 milliseconds from the onset of the step (Figure 2A) 12 In HCM versus control samples, mRNA expression and protein expression of the cardiac Na + channel (NaV1.5) were unchanged ( Figure 2C ). As shown below, APD shortening by ranolazine, a selective blocker of I NaL , suggests that increased I NaL plays a major role in prolonging the APD of HCM cardiomyocytes.
L-type Ca 2+ current (I CaL ) density was significantly increased in HCM cardiomyocytes compared with controls at all voltages ( Figure 2B ). Consistently, increased expression of CaV1.2 protein was found in HCM myocardium, associated with transcriptional upregulation of the gene coding for the I CaL channel, CaCNA1.2 ( Figure 2C ). Additionally, the fast and slow kinetics of I CaL inactivation were both slower in HCM cardiomyocytes ( Figure 2B and 2D) , and Ca 2+ -dependent facilitation was abolished ( Figure II in the online-only Data Supplement), suggesting posttranslational modifications of the I CaL channel.
With regard to repolarizing K + currents, HCM cardiomyocytes had a significant reduction in transient outward current (I to ) and inward rectifier potassium current (I k1 ) densities ( Figure 2E and 2F). These findings were associated with a general reduction in mRNA expression of genes coding for K + channels subunits, including I to and I k1 subunits ( Figure  2G ). Selective downregulation of the K + channels at the transcriptional control level was also suggested by the increased expression of their regulatory microRNA miR-1 13 in HCM specimens ( Figure 2G ).
The observed changes in Ca, 2+ late Na + , and K + current densities were introduced into a validated mathematical model of human ventricular myocyte 14 (see the Methods section in the online-only Data Supplement), confirming that HCMrelated current changes account for APD prolongation in HCM cardiomyocytes ( Figure III in the online-only Data Supplement).
Alterations of Ca 2+ Transients and Diastolic Ca
2+
The amplitude of Ca 2+ i transients evoked in current-clamp conditions was similar in HCM and control cardiomyocytes ( Figure 3A and 3B) . However, the kinetics of Ca 2+ i transients, as indicated by time to peak and decay time, was significantly slower in HCM compared with control cardiomyocytes Figure 3D ). This observation suggests that, besides APD prolongation, perturbations in other components of excitation-contraction coupling are responsible for the observed abnormalities of Ca 2+ handling. Factors likely involved in these perturbations were the following: Figure 3E ) was significantly increased in HCM compared with control cardiomyocytes (Figure 3F ), possibly promoting diastolic Ca 2+ leakage, with potential effects on diastolic [Ca] 2+ i and the rate of DADs. Figure 3G and Figure IV in the online-only Data Supplement). In agreement with a previous observation in HCM myocardium, 18 reduced SERCA activity may contribute to the slowing of Ca 2+ transient decay.
Inhibition of I NaL Reverses Alterations of APD and Intracellular Ca 2+ Handling
Functional analysis of HCM cardiomyocytes pointed to higher I NaL as a key determinant of the electrophysiological and excitation-contraction coupling abnormalities. We therefore assessed the effects of ranolazine, a selective I NaL inhibitor, 19 on the electromechanical dysfunction of HCM cardiomyocytes.
In control cardiomyocytes, ranolazine (10 µmol/L) did not significantly affect the APD or the amplitude and kinetics of Ca 
Contractile Function of HCM Trabeculae: I NaL Inhibition Improves Diastolic Function
The contractile function of HCM myocardium was investigated using intact ventricular trabeculae dissected from the endocardial layer of myectomy specimens (Figure XI in the online-only Data Supplement). Measurements of active tension in these preparations consistently showed that the HCM muscle displays a positive force-frequency relationship (Figure 5A and 5B), in contrast to failing human myocardium 21 or end-stage human HCM. 22 In addition, muscle contractile reserve was preserved, as indicated by the positive inotropic response to isoproterenol. High external [Ca]
2+
, and stimulation pauses ( Figure 5C , 5D, and 5E), in agreement with the maintained Ca that reported for the myocardium of healthy donors 22 and with preliminary data from control trabeculae ( Figure 5B ).
Ranolazine (10 µmol/L) shortened the overall twitch duration of intact HCM trabeculae, primarily by increasing the speed of force development ( Figure 5F and 5G), and significantly reduced diastolic tension ( Figure 5F and 5H). The faster [Ca] 2+ i transient kinetics and lower diastolic [Ca] 2+ i seen in HCM cardiomyocytes on ranolazine likely account for the shortening of twitch duration and the reduction in diastolic tension in trabeculae. Finally, ranolazine tended to reduce peak isometric (active) force and the inotropic reserve of HCM myocardium ( Figure 5F and 5K).
In trabeculae from septal samples of control patients, I NaL inhibition with ranolazine did not exert any significant effects on contractile parameters (Figure VI in the online-only Data Supplement), consistent with the lack of effect on Ca 2+ handling observed in control cardiomyocytes.
Mechanisms Underlying Electrophysiological and Ca
2+ Handling Abnormalities in HCM: Role of Enhanced CaMKII Activity.
CaMKII cascade plays a critical role in driving disease-related cardiomyocyte remodeling in cardiac diseases 24 and, pertaining to this study, I NaL gain of function. 25 We investigated the mechanistic role of CaMKII in HCM by comparing the level of CaMKII activation and phosphorylation of its downstream targets in HCM and control specimens. CaMKII autophosphorylation was increased 3.5-fold in HCM samples, indicating increased activity 26 ( Figure 6A) . In addition, all tested targets showed increased phosphorylation at specific sites for CaMKII, including L-type Ca 2+ channel, ryanodine receptor 2, and phospholamban ( Figure 6A ). The 1.5-fold increase in CaMKII-dependent phosphorylation of L-type Ca 2+ channel is likely responsible for the slower inactivation of I CaL 27 observed in HCM cardiomyocytes ( Figure  2B and 2D) . Similarly, 1.5-fold higher CaMKII-dependent phosphorylation of ryanodine receptor 2 may contribute to susceptibility to DADs 28 ( Figure 1D ). The observed 3-foldhigher phosphorylation of phospholamban, by relieving SERCA inhibition, may partially counteract the effects of reduced SERCA expression and increase SR Ca 2+ load in HCM cardiomyocytes 29 ( Figure 3G ). Furthermore, coimmunoprecipitation data suggest increased CaMKII phosphorylation of the cardiac Na + channel Nav1.5 ( Figure 6B ), which is notably associated with delayed current inactivation. 25 CaMKII activation may therefore be the primary determinant of I NaL augmentation in HCM cardiomyocytes, albeit other mechanisms can be involved.
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Discussion
In the present study, we comprehensively addressed the adaptive (and maladaptive) mechanisms occurring at the cellular level in human HCM myocardium. We demonstrated that the functional phenotype of isolated cardiomyocytes derived from HCM patients differs significantly from that of controls. Of note, similar alterations have been described in other models of cardiac hypertrophy (although to a milder degree) but differ markedly from the global myocardial dysfunction seen in terminally failing human hearts. 31 Interestingly, these changes appear to be significant determinants of the main pathophysiological features of HCM in patients: longer action potentials and increased incidence of EADs and DADs underlie increased arrhythmogenicity, and prolonged intracellular Ca 2+ transients and higher diastolic [Ca] 2+ i may account for abnormal muscle contraction and contribute to diastolic dysfunction in patients.
Sustained activation of CaMKII-dependent signaling pathway appears to play a central role in the regulation of cardiomyocyte remodeling in HCM (Figure 7) . By slowing down I CaL inactivation and increasing I NaL amplitude, enhanced CaMKII activity contributes to APD prolongation and related arrhythmias. In addition, by altering the function of excitation-contraction coupling proteins, CaMKII might contribute to the altered Ca -bound calmodulin is the primary activator of the kinase. 32 Of note, a sustained increase in intracellular [Ca] 2+ is one of the established consequences of HCMrelated sarcomeric mutations, either resulting from increased Ca 2+ sensitivity of myofilaments 33 or stemming from the higher energy requirements of mutant sarcomeric proteins, 34 leading to lower ATP availability for SERCA function (Figure 7) . Indeed, we found that Ca 2+ sensitivity of force generation, measured from skinned preparations obtained from the same specimens, is increased in HCM compared with control myocardium ( Figure  XI (Figure 7) .
The striking effects of ranolazine in HCM cardiomyocyte compared with the relative lack of effects in control cardiomyocytes highlight the central role of I NaL augmentation in the electromechanical abnormalities of HCM myocardium (Figure 7) . Increased I NaL , paralleled by augmented I CaL and diminished K + currents, appears to underlie APD prolongation and cellular arrhythmias in HCM. Indeed, I NaL block by ranolazine shortens APD and reduces EADs in HCM cardiomyocytes. As shown in Figure 7 , enhanced I NaL leads to increased Na + entry during the plateau of the action potential, resulting in higher intracellular Na + concentrations in HCM cardiomyocytes, particularly at faster stimulation frequencies. Ranolazine has been shown to reduce arrhythmias 40 and diastolic dysfunction 41 in patients with ischemic heart disease. Our observations indicate that I NaL inhibition has the potential to be an important therapeutic strategy for HCM treatment, possibly by addressing key clinical manifestations of the disease such as ventricular tachyarrhythmias and diastolic dysfunction. 2 The results reported here provide a strong rationale for clinical studies assessing the efficacy of ranolazine in this orphan disease. 6 
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CLINICAL PERSPECTIvE
Hypertrophic cardiomyopathy (HCM), despite being the most prevalent monogenic cardiac disorder, remains an orphan of disease-specific pharmacological treatment. Altered electric and mechanical function of cardiac myocytes is credited as a fundamental pathophysiological feature of HCM, responsible for manifestations ranging from ventricular arrhythmogenicity to diastolic dysfunction. To date, however, the cellular basis of electromechanical dysfunction in cardiomyocytes from HCM patients and the presence of related therapeutic targets are unresolved. We compared the electromechanical profile of single cardiomyocytes isolated from the surgical specimens of 26 HCM patients undergoing septal myectomy with those of surgical patients without left ventricular hypertrophy. Using patch-clamp measurements and studies of intracellular calcium fluxes, we identified several alterations in HCM cardiomyocytes, including prolongation of action potential, slower calcium dynamics, and higher diastolic tension, favoring arrhythmogenesis and diastolic dysfunction. Intriguingly, all these anomalies were subtended by a marked increase in the membrane late sodium current, which represents a viable therapeutic target in humans owing to the clinical availability of a selective blocker, ranolazine. Indeed, ranolazine at therapeutic concentrations counteracted most of the abnormalities observed in vitro in HCM cardiomyocytes. Specifically, ranolazine reduced the occurrence of early and delayed afterdepolarizations by shortening action potential duration and ameliorated myocardial diastolic function via normalization of intracellular Ca 2+ dynamics. These findings suggest a beneficial effect of late sodium current inhibition in HCM patients, which may ultimately be relevant for the management of arrhythmias and diastolic dysfunction, providing a strong rationale for future clinical studies assessing the efficacy of ranolazine in this disease. recordings, only 0.3mM CdCl 2 was added. I to recordings were carried out 21-23°C using depolarizations steps as described before 7 . To measure I k1 , voltage ramps from -120mV to +40mV were applied at 35°C. I K1 I-V relationships were estimated from the difference between total current in the absence and presence of 2mM BaCl 2 8 .
SUPPLEMENTAL MATERIAL
Late sodium current (I NaL ) was measured as described before 9 . In brief, I NaL was elicited using a 0.25Hz train of pulses to -20mV from -120mV holding potential: 10 subsequent episodes were averaged. The current was then elicited 10 times in the presence of 10µM ranolazine. Afterwards, tetrodotoxin (TTX, 30µM) was added and the protocol repeated. To block the cardiac Na + channels completely, we employed a (over)maximal TTX concentration (30 µM), which allowed us to obtain a "zero Na + current level" that is used as reference.I NaL was then estimated as the difference between the traces recorded in the absence and in the presence of TTX (TTX-corrected traces). The integral of TTX-corrected I NaL between 50 and 750ms after the onset of depolarization was finally calculated for each myocyte in each condition (e.g. presence or absence of ranolazine).
Potential and current signals were measured with a Multiclamp 700B amplifier. Patch-clamp and fluorescence signals were simultaneously digitized through using Digidata 1440A. Acquisition and analysis was controlled by dedicated software (pClamp10.0). All products from Molecular Devices, Sunnyvale, California.
EADs and DADs: EAD and DAD events were considered when a spontaneous depolarization larger than 20mV was detected during the plateau of an AP or during the diastolic period, respectively. A cardiomyocyte was scored positive for EADs or DADs if it displayed > 2 events during 3'of stimulated activity.
Ranolazine cell studies: test recordings in presence of 10µM ranolazine were performed after >3
minutes from the beginning of drug exposure and repeated after >5minutes of washout.
[ were incubated with fluorescent dye Asante NaTRIUM Green-2 AM (Teflabs, Austin, Texas) for 45 min at room temperature and left settling for another 30 min after dye withdrawal to allow complete dye deesterification 10 . Excitation light was set at at 514 nm, and fluorescence was acquired at wavelengths >527 nm. Measurements were performed at 35 ±0.5 °C. All fluorescence measurements were normalized by the maximal fluorescence value in each cell, obtained by mechanically permeabilizing the cell at the end of the experiment. Intracellular Na + was monitored during stimulation at 3 different pacing rates (0.1, 0.5 and 1Hz) in current-clamp mode while recording membrane action potential. Of note, the relatively large dynamic interval of this novel dye combined with the high response speed (when compared to older dyes such as SBFI) allowed recording of intracellular sodium movements during the course of a single activation cycle, as previously observed 11 .
Intact trabeculae studies: Intact ventricular trabeculae were mounted between a basket-shaped end of a force transducer (KG7A, Scientific Instruments Heidelberg, Germany) and a motor (Aurora Scientific Inc., Aurora, Canada), controlled by a custom Labview (National Instruments, Austin,Texas) program.
Muscles were mounted in cold cardioplegic solution and then perfused with Krebs/Henseleit buffer, containing (in mM) 119 NaCl, 4.7 KCl, 2.5 CaCl 2 , 1.2 MgSO 4 , 1.2 KH 2 PO 4 , 25 NaHCO 3 ; pH 7.4 with 95%O 2 :5%CO 2 . Muscles were allowed to stabilize for at least 30 min before recordings. Diastolic sarcomere length was assessed by calculating the average distance of striations and set at 2.10-2.20 µm. Isometric force was recorded at 35±2°C under various conditions. In brief, inotropic responses to increased pacing frequencies, stimulation pauses and beta-adrenoceptor agonist isoproterenol (10 -7 M) were evaluated and kinetics of isometric twitches was assessed under all conditions. The trabecula was stimulated at increasing pacing rates (0.1-2.5 Hz): at each frequency, force was allowed to reach steady-state before recordings.
Stimulation pauses (30s) were inserted after the last contraction of a steady series (at 0.5 Hz) and post-rest potentiation was evaluated at the first stimulated beat after the pause. Large (>10% of muscle length) motorinduced shortening steps allowed assessment of diastolic tension. The effects of drugs (Ranolazine 10µM, Isoproterenol 0.1 µM) were evaluated >20 minutes after adding them to the recirculating buffer and measurements repeated after >15minutes of washout. Finally, muscle section was measured for force normalization.
Mechanical studies on skinned trabeculae: In order to assess myofilament function, muscle strips and trabeculae were skinned by overnight incubation in relaxing solution added with 0.5% Triton X100.
Triton was then removed and the skinned preparations were mounted horizontally between a force transducer and a motor by means of T-clips. Muscles were activated by transferring them manually between baths containing different pCa solutions and the pCa-force relationship was determined. Three types of solutions were employed: relaxing solution (pCa 9) with 5 mM EGTA, pre-activating solution with 0.5 mM EGTA RT-PCR: mRNA isolated from septal specimens underwent reverse transcription and the resulting cDNA was employed for quantitative real time PCR using predesigned assays for the following genes:
Kv4.3, KChIP, HERG2b, KCNQ1, CaCNA1.2, NaV1.5, NCX1, PLB, SERCA2a and RYR2.Total RNA from each frozen cardiac sample was isolated and DNase-treated with the RNeasy Fibrous Tissue Mini Kit (Qiagen) following manufacturer's instructions. Single-stranded cDNA was synthesized from 2 µg total RNA using the High Capacity cDNA Reverse Transcription Kit (Applied Biosystems) as described before 12 . The genes selected for quantification were investigated using predesigned TaqMan® Gene Expression assays (Applied BioSystems, USA). All reactions were performed in triplicate and included a negative control.
Relative quantification of the mRNA level for the different genes was determined by the 7500 system software (Applied BioSystems, USA), using the comparative method (∆∆Ct). In brief, the threshold cycle Relative intensity of individual bands from Western blots was quantitated using ImageJ software and normalized to GAPDH. The ratio for control was assigned a value of 1. Chemicals: unless otherwise specified, all chemicals were purchased from Sigma-Aldrich,St. Louis, MO.
Mathematical model:
To obtain a control human cardiomyocyte model, we used a validated model of human ventricular cardiomyocyte 13 , recently developed by Grandi and Bers. Simulation of I NaL was added to the original model (as done by Wu et al. 14 ) using a Hodgkin-Huxley formalism, similar to that used by Hund et al. 15 :
I NaL activation (gating variable, m) is similar the activation of the fast I Na , whereas inactivation of I NaL (gating variable, h) was formulated as shown below:
I NaL maximal conductance (G NaL ) was set to 0.085 mS/µF to simulate a larger endogenous I NaL in human ventricular myocytes compared to dog myocytes 15 .
To simulate HCM cardiomyocytes in agreement with our results, we introduced the following changes to the control cell model:
(1)107% increase of I NaL maximal conductance; (2) 34% decrease of I kr maximal conductance; (3) 27% decrease of I ks maximal conductance; (4) 85% decrease of I to maximal conductance; (5) 15% decrease of I k1 conductance; (6) 19% increase of I CaL maximal conductance; (7) 34% increase of NCX activity; (8) 43%
reduction of SERCA activity.
Model differential equations were implemented in COR 16 To faithfully compare different sets of measurements, sensitivity analysis was performed for each statistical comparison, in order to account for:
1-non Gaussian distribution
The data were tested for normality using the Skewness/Kurtosis test 17 .
2-heteroschedasticity (inequality of variances)
We used the F test for equality of variances in two-group comparison studies and the Bartlett's test for variance homogeneity in the multiple comparison design.
Non-parametric test based on rank transformation (Wilcoxon's sum of rank) was used to check robustness of results under violation of condition 1-or 2-.
3-within-subject correlation
Most of the average data derives from multiple myocytes or trabecuale from different patients. We estimated within-subject correlation for each variable with One-way ANOVA. In order to account for the correlation among different cells/muscles from the same patient, we used linear mixed models 18 to compare couples of data groups, both paired and unpaired. Correction for heteroschedasticity was applied to linear mixed models in unpaired comparisons whenever the variances of the two groups were unequal (as calculated by F-test).
All the results of the new statistical analysis are available on request. The Probability (P) values that are shown in the manuscript and in the online supplement were calculated with linear mixed models according to the aforementioned procedure, both when comparing repeated measurements on the same samples (e.g. effect of ranolazine) and when comparing unpaired datasets. P-values <0.05 were considered statistically significant.
To quantify EADs and DADs occurrence and its confidence intervals, the binomial proportion confidence interval was calculated as approximating the binomial distribution with a normal distribution (central limit theorem). The confidence interval was calculated as:
where p is the fraction of successes in a Bernoulli trial process estimated from the statistical sample and N is the sample size. In our case p is the fraction of myocytes scored positive for EAD or DAD events as described above.
The central limit theorem was not applied to a binomial distribution where the fraction p  0. In these cases the Wilson score interval was applied:
The statistical significance of differences in DAD or EAD occurrence was assessed using the Fisher exact test. Statistical analysis was performed using Stata 12 software (StataCorp LP, College Station, Texas, USA). 
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Step ; pCa 50 was 5.93±0.07 and 5.61±0.02 in HCM and control preparations respectively (p<0.05); n H was 1.99±0.41 and 2.98±0.25 in HCM and control preparations respectively (p=0.08). The left-shifted pCa-force relationship in HCM patients indicates that changes in myofilament function (e.g. increased Ca 2+ -sensitivity) may also contributes to altered intracellular Ca 2+ levels and E-C coupling abnormalities in HCM myocardium.
